Loading...
4 results
Search Results
Now showing 1 - 4 of 4
- Therapeutic potential of vanadium complexes with 1,10-phenanthroline ligands, quo vadis? Fate of complexes in cell media and cancer cellsPublication . Nunes, Patrique; Correia, Isabel; Cavaco, Isabel; Marques, Fernanda; Pinheiro, Teresa; Avecilla, Fernando; Pessoa, Joao Costa(VO)-O-IV-complexes formulated as [(VO)-O-IV(OSO3)(phen)(2)] (1) (phen = 1,10-phenanthroline), [(VO)-O-IV(OSO3) (Me(2)phen)(2)] (2) (Me(2)phen = 4,7-dimethyl-1,10-phenanthroline) and [(VO)-O-IV(OSO3)(amphen)(2)] (3) (amphen = 5-amino-1,10-phenanthroline) were prepared and stability in cell incubation media evaluated. Their cytotoxicity was determined against the A2780 (ovarian), MCF7 (breast) and PC3 (prostate) human cancer cells at different incubation times. While at 3 and 24 h the cytotoxicity differs for complexes and corresponding free ligands, at 72 h incubation all compounds are equally active presenting low IC50 values. Upon incubation of A2780 cells with 1-3, cellular distribution of vanadium in cytosol, membranes, nucleus and cytoskeleton, indicate that the uptake of V is low, particularly for 1, and that the uptake pattern depends on the ligand. Nuclear microscopic techniques are used for imaging and elemental quantification in whole PC3 cells incubated with 1. Once complexes are added to cell culture media, they decompose, and with time most V-IV oxidizes to V-V-species. Modeling of speciation when [(VO)-O-IV(OSO3)(phen)(2)] (1) is added to cell media is presented. At lower concentrations of 1, (VO)-O-IV- and phen-containing species are mainly bound to bovine serum albumin, while at higher concentrations [(VO)-O-IV (phen)n](2+)-complexes become relevant, being predicted that the species taken up and mechanisms of action operating depend on the total concentration of complex. This study emphasizes that for these (VO)-O-IV-systems, and probably for many others involving oxidovanadium or other labile metal complexes, it is not possible to identify active species or propose mechanisms of cytotoxic action without evaluating speciation occurring in cell media.
- Cytotoxicity of Cryptosula zavjalovensis Kubanin extract against Breast Cancer Cell Line MCF7Publication . Gonzaga, Loveille Jun; Cavaco, Isabel; Fortunato, HelenaThe marine environment is an abundant source of diverse biologically active compounds that demonstrate great potential applications in pharmaceutics and medicine. Although novel biologically active secondary metabolites can be potentially found in bryozoans, there have been a few studies on these organisms. Bryozoans are sessile colonial animals commonly found in great diversity in shallow waters. In this study, samples of the bryozoan Cryptosula zavjalovensis Kubanin were collected from Akkeshi, Japan, and were extracted using ethanol. The crude extract was separated using ethyl acetate (EtOAc) and water to obtain organic and aqueous fractions, respectively. In the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the EtOAc fraction demonstrated cytotoxicity towards MCF7 breast cancer cells. The EtOAc extract was subsequently fractionated through solid-phase extraction using a gradient of methanol and water (E1 80:20 v/v and E2 100:0 v/v) and using methanol and chloroform (E3 50:50 v/v). Toxicity profiling revealed that the toxicity toward the human MCF7 breast cancer cells of the E2 and E3 fractions is comparable to that of cisplatin, indicating the excellent cytotoxic activity of the EtOAc fractions of C. zavjalovensis. Further studies are thus warranted to isolate the novel compounds in these fractions and determine their potential chemotherapeutic application.
- New Cu(II) complexes with pyrazolyl derived schiff base ligands: synthesis and biological evaluationPublication . Ribeiro, Nadia; Roy, Somnath; Butenko, Nataliya; Cavaco, Isabel; Pinheiro, Teresa; Alho, Irina; Marques, Fernanda; Avecilla, Fernando; Pessoa, Joao Costa; Correia, IsabelSince the discovery of cisplatin there has been a continuous pursuit for new metallodrugs showing higher efficacies and lower side effects. In this work, new copper(II) complexes (C1-C6) of Schiff bases derived from pyrazolyl were developed. Through condensation of 5-methyl-1H-pyrazole-3-carbohydrazide with different aromatic aldehydes - pyridoxal, salicylaldehyde, 3-methoxy-2-hydroxybenzaldehyde, 3-ethoxy-2-hydroxybenzaldehyde and 2-hydroxynaphthene-l-carbaldehyde a set of new pyrazole based "ONO" tridentate Schiff bases were obtained in moderate to good yields - L1-L6, as well as their Cu(II)-complexes. All compounds were characterized by analytical techniques and their molecular formulae established. The antioxidant potential of all compounds was tested, yielding low activity in most cases, with the exception of L1 and C5. The Cu(II) complexes were tested for their aqueous stability, and for their interaction with biological molecules, namely DNA and HSA (human serum albumin), through fluorescence quenching experiments (and electrophoresis for DNA). With the exception of C3, all the synthesized complexes were able to interact with DNA and HSA. Their cytotoxic activity against two cancer cell lines (MCF7 - breast and PC3 - prostate) was also evaluated. Complexes C5 and C6, with larger aromatic systems, showed much higher cytotoxicity (in the low mu M range), than C1-C4, as well as IC50 values much lower than cisplatin. For C6 the results suggest that the mechanisms of cell death do not seem to be mediated by apoptosis, through caspases 3/7 activation, but by involving membrane potential and imbalance in physiological elements such as P, K and Ca.
- Exploring the therapeutic potential of Cu(II)-complexes with ligands derived from pyridoxalPublication . Nunes, Patrique; Marques, Fernanda; Cavaco, Isabel; Pessoa, Joao Costa; Correia, IsabelThree new copper(II) complexes formulated as [Cu(L)(X)], where X = H2O or Cl and H2L is a Schiff base (H2L1,2) or its reduced version ((H3LCl)-Cl-3) derived from pyridoxal, are prepared, as well as two ternary complexes [Cu(L) (phen)] also containing 1,10-phenanthroline. All compounds are characterized by the usual techniques: elemental analyses, ESI mass spectrometry, UV-Vis absorption, FTIR and EPR spectroscopies. The ligands co-ordinate the Cu(II) center forming complexes with square-planar based geometries. Their antioxidant properties are evaluated with a radical scavenging activity assay, with one of the ligand precursors showing activity higher than the positive control, ascorbic acid. The antiproliferative activity of all compounds is evaluated against two cancer cell lines: ovarian (A2780) and breast (MCF7). All complexes show moderate to excellent activity with the ternary Cu-complexes showing IC50 values between 0.7 and 9.3 mu M after 24 h of incubation, values much lower than those reported for cisplatin, the reference drug. The hydrolytic stability of the complexes and their ability to bind albumin and DNA are evaluated by spectroscopic techniques, showing that the compounds bind bovine serum albumin. The [Cu(L)(phen)] complexes show ability to target DNA via intercalation.